Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease

2008 ◽  
Vol 23 (11) ◽  
pp. 1546-1550 ◽  
Author(s):  
Gisela Llebaria ◽  
Javier Pagonabarraga ◽  
Jaime Kulisevsky ◽  
Carmen García-Sánchez ◽  
Berta Pascual-Sedano ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Mattis Dementia Rating Scale ◽  
Dementia Rating Scale

scholarly journals Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale‐2 in Parkinson's disease

2018 ◽  
Vol 34 (2) ◽  
pp. 285-291 ◽  
Author(s):  
Taylor R. Hendershott ◽  
Delphine Zhu ◽  
Seoni Llanes ◽  
Cyrus P. Zabetian ◽  
Joseph Quinn ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Comparative Sensitivity ◽  
Mattis Dementia Rating Scale ◽  
Dementia Rating Scale

The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment

2014 ◽  
Vol 20 (6) ◽  
pp. 627-631 ◽  
Author(s):  
Eva Pirogovsky ◽  
Dawn M. Schiehser ◽  
Irene Litvan ◽  
Kristalyn M. Obtera ◽  
Mathes M. Burke ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Rating Scale ◽  
Mattis Dementia Rating Scale ◽  
Dementia Rating Scale

Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data

2015 ◽  
Vol 39 (5-6) ◽  
pp. 303-311 ◽  
Author(s):  
Ondrej Bezdicek ◽  
Jiri Michalec ◽  
Tomas Nikolai ◽  
Petra Havránková ◽  
Jan Roth ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Normative Data ◽  
Rating Scale ◽  
Mattis Dementia Rating Scale ◽  
Level Ii ◽  
Dementia Rating Scale ◽  
Level I

Background/Aims: The aim of the present study was to provide normative data and determine the validity of the Czech version of the Mattis Dementia Rating Scale 2 (czDRS-2) in screening for mild cognitive impairment in Parkinson's disease (PD-MCI) based on the Movement Disorder Society (MDS) Level II criteria. Methods: For validation purposes, 41 healthy controls (HC), 46 patients with PD-NI (Parkinson's disease, no impairment) and 41 patients with PD-MCI (all groups assessed by the MDS Level II criteria for PD-MCI) were matched according to age and education. Results: With screening and diagnostic cutoff scores determined at ≤139 points, the czDRS-2 showed a sensitivity of 78% and a specificity of 88% in the detection of PD-MCI versus HC and a sensitivity of 78% and a specificity of 76% in the detection of PD-MCI versus PD-NI. The AUC (95% confidence interval) for the czDRS-2 was 84% (75-93) and 82% (73-91), respectively. We report percentile values for 286 subjects from the Czech population stratified by education level. Conclusion: Our results show that the czDRS-2 is a valid instrument at Level I for screening PD-MCI and support its construct validity and diagnostic equivalence in a cross-cultural setting.

Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson’s disease

2006 ◽  
Vol 253 (9) ◽  
pp. 1154-1159 ◽  
Author(s):  
Kathy Dujardin ◽  
David Devos ◽  
Stéphane Duhem ◽  
Alain Destée ◽  
Rose-Marie Marié ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Rating Scale ◽  
Mattis Dementia Rating Scale ◽  
Dementia Rating Scale

Validity of the Dementia Rating Scale in Assessing Cognitive Function in Parkinson's Disease

1999 ◽  
Vol 12 (4) ◽  
pp. 180-188 ◽  
Author(s):  
Gregory G. Brown ◽  
Alice Armstrong Rahill ◽  
Jay M. Gorell ◽  
Cathleen McDonald ◽  
Sandra J. Brown ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Function ◽  
Rating Scale ◽  
Dementia Rating Scale

scholarly journals Test the Best: Classification Accuracies of Four Cognitive Rating Scales for Parkinson’s Disease Mild Cognitive Impairment

2020 ◽  
Vol 35 (7) ◽  
pp. 1069-1077
Author(s):  
Adela Fendrych Mazancova ◽  
Evžen Růžička ◽  
Robert Jech ◽  
Ondrej Bezdicek
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Rating Scales ◽  
Rating Scale ◽  
Screening Tools ◽  
Cutoff Score ◽  
Neuropsychological Battery ◽  
Mattis Dementia Rating Scale

Abstract Objective A progressive cognitive impairment is one of the frequent non-motor symptoms during Parkinson’s disease (PD) course. A short and valid screening tool is needed to detect an incipient cognitive deficit at the mild cognitive impairment stage in Parkinson’s disease (PD–MCI). Method The present study aims to evaluate the classification accuracies of four cognitive screenings: Montreal Cognitive Assessment (MoCA), Mattis Dementia Rating Scale second edition (DRS–2), Mini-Mental State Examination (MMSE) and Frontal Assessment Battery (FAB) in a cohort of PD patients (PD–MCI, n = 46; and Parkinson’s disease with normal cognition, PD-NC, n = 95) and Controls (n = 66). All subjects underwent a standard neuropsychological battery as recommended by the International Parkinson and Movement Disorder Society and underwent all four screening tools. Results In the detection of PD-MCI versus PD-NC, the MoCA showed a sensitivity of 84% and a specificity of 66% with a screening cutoff score at ≤25 points. The MoCA’s AUC was 86% (95% CI 78.7–93.1). In the detection of PD-MCI versus Controls, the FAB displayed 84% sensitivity and 79% specificity with a cutoff ≤16 points, to screen. The FAB’s AUC was 87% (79.0–95.0). Conclusions Our results show that the MoCA is the most discriminative tool for screening MCI in the PD population.

scholarly journals Screening Mild and Major Neurocognitive Disorders in Parkinson’s Disease

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Tivadar Lucza ◽  
Kázmér Karádi ◽  
János Kállai ◽  
Rita Weintraut ◽  
József Janszky ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Diagnostic Accuracy ◽  
Rating Scale ◽  
Cognitive Disorder ◽  
Screening Tests ◽  
Diagnostic And Statistical Manual ◽  
Dsm 5 ◽  
Mattis Dementia Rating Scale ◽  
State Examination

Introduction. Among the nonmotor features of Parkinson’s disease (PD), cognitive impairment is one of the most troublesome problems. New diagnostic criteria for mild and major neurocognitive disorder (NCD) in PD were established by Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5). The aim of our study was to establish the diagnostic accuracy of widely used screening tests for NCD in PD.Methods. Within the scope of our study we evaluated the sensitivity and specificity of different neuropsychological tests (Addenbrooke’s Cognitive Examination (ACE), Mattis Dementia Rating Scale (MDRS), Mini Mental State Examination (MMSE), and Montreal Cognitive Assessment (MoCA)) in 370 PD patients without depression.Results. MoCA and ACE feature the finest diagnostic accuracy for detecting mild cognitive disorder in PD (DSM-5) at the cut-off scores of 23.5 and 83.5 points, respectively. The diagnostic accuracy of these tests was 0.859 (95% CI: 0.818–0.894, MoCA) and 0.820 (95% CI: 0.774–0.859, ACE). In the detection of major NCD (DSM-5), MoCA and MDRS tests exhibited the best diagnostic accuracy at the cut-off scores of 20.5 and 132.5 points, respectively. The diagnostic accuracy of these tests was 0.863 (95% CI: 0.823–0.897, MoCA) and 0.830 (95% CI: 0.785–0.869, MDRS).Conclusion. Our study demonstrated that the MoCA may be the most suitable test for detecting mild and major NCD in PD.

Sign in / Sign up

Export Citation Format

Share Document